Researchers continue investigating how hemp-derived cannabinoids may interact with brain pathways connected to mood, memory, and cognitive health. In the review “Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models,” scientists examined how cannabinoids such as CBD, CBG, CBC, and other non-psychotropic compounds affected depression-related behaviors and cognitive performance in laboratory and animal studies. The review focused on how cannabinoids may interact with neurotransmitters, inflammation pathways, oxidative stress, and the body’s endocannabinoid system.

The research highlighted that phytocannabinoids demonstrated anti-inflammatory, antioxidant, and neuroprotective activity in multiple preclinical models. Researchers observed that cannabinoids may help regulate serotonin signaling, reduce neuroinflammation, and support healthy brain-cell communication. Several cannabinoids also appeared to influence pathways associated with stress response, memory, mood regulation, and cognitive function. These findings continue supporting growing scientific interest in cannabinoids and their potential role in supporting neurological wellness and emotional balance.

The review also discussed the importance of the endocannabinoid system in maintaining brain health and how cannabinoid diversity may contribute to what researchers often call the “entourage effect.” While additional human clinical studies are still needed, ongoing research continues expanding scientific understanding of how broad-spectrum and multi-cannabinoid hemp formulations may support overall wellness, mood balance, and cognitive health.

Source

Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models. Published January 2026. https://pubmed.ncbi.nlm.nih.gov/41934896/